184 related articles for article (PubMed ID: 37586782)
21. A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda.
Ngabo F; Levin A; Wang SA; Gatera M; Rugambwa C; Kayonga C; Donnen P; Lepage P; Hutubessy R
Vaccine; 2015 Dec; 33(51):7357-7363. PubMed ID: 26519548
[TBL] [Abstract][Full Text] [Related]
22. Strengthening national teams of experts to support HPV vaccine introduction in Eastern Mediterranean countries: Lessons learnt and recommendations from an international workshop.
Dochez C; Al Awaidy S; Mohsni E; Fahmy K; Bouskraoui M
Vaccine; 2020 Jan; 38(5):1114-1119. PubMed ID: 31771862
[TBL] [Abstract][Full Text] [Related]
23. School-based vaccination programmes: An evaluation of school immunisation delivery models in England in 2015/16.
Tiley K; Tessier E; White JM; Andrews N; Saliba V; Ramsay M; Edelstein M
Vaccine; 2020 Mar; 38(15):3149-3156. PubMed ID: 31980192
[TBL] [Abstract][Full Text] [Related]
24. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania.
Quentin W; Terris-Prestholt F; Changalucha J; Soteli S; Edmunds WJ; Hutubessy R; Ross DA; Kapiga S; Hayes R; Watson-Jones D
BMC Med; 2012 Nov; 10():137. PubMed ID: 23148516
[TBL] [Abstract][Full Text] [Related]
25. Introducing human papillomavirus vaccines into the health system in South Africa.
Botha MH; Dochez C
Vaccine; 2012 Sep; 30 Suppl 3():C28-34. PubMed ID: 22939017
[TBL] [Abstract][Full Text] [Related]
26. HPV vaccination's second act: promotion, competition, and compulsion.
Schwartz JL
Am J Public Health; 2010 Oct; 100(10):1841-4. PubMed ID: 20724671
[TBL] [Abstract][Full Text] [Related]
27. The impact of HPV vaccination delays in China: lessons from HBV control programs.
Colombara DV; Wang SM
Vaccine; 2013 Aug; 31(38):4057-9. PubMed ID: 23777955
[No Abstract] [Full Text] [Related]
28. Mandating HPV vaccination: what are the arguments?
Smith CM
J Christ Nurs; 2008; 25(2):74-80; quiz 81-2. PubMed ID: 18401926
[No Abstract] [Full Text] [Related]
29. The current status of HPV and rotavirus vaccines in national immunisation schedules in the EU--preliminary results of a VENICE survey.
Kudjawu Y; Lévy-Bruhl D; Celentano LP; O'Flanagan D; Salmaso S; Lopalco P; Mullins N; Bacci S;
Euro Surveill; 2007 Apr; 12(4):E070426.1. PubMed ID: 17868608
[No Abstract] [Full Text] [Related]
30. Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia.
Watson M; Shaw D; Molchanoff L; McInnes C
Aust N Z J Public Health; 2009 Aug; 33(4):365-70. PubMed ID: 19689598
[TBL] [Abstract][Full Text] [Related]
31. Potential process improvements to increase coverage of human papillomavirus vaccine in schools - A focus on schools with low vaccine uptake.
Selvey LA; Roux F; Burns S
Vaccine; 2020 Mar; 38(14):2971-2977. PubMed ID: 32115296
[TBL] [Abstract][Full Text] [Related]
32. [The first HPV vaccine is now available].
Kjaer SK; Olesen F; Toftager-Larsen K; Sand C; Strauss GI; Hoffmann TU; Ottesen BS
Ugeskr Laeger; 2006 Oct; 168(44):3827-8. PubMed ID: 17118245
[TBL] [Abstract][Full Text] [Related]
33. Safety of HPV vaccines in the age of nonavalent vaccination.
Quattrone F; Canale A; Filippetti E; Tulipani A; Porretta A; Lopalco PL
Minerva Pediatr; 2018 Feb; 70(1):59-66. PubMed ID: 29363293
[TBL] [Abstract][Full Text] [Related]
34. Qualitative study of the feasibility of HPV vaccine delivery to young adolescent girls in Vietnam: evidence from a government-implemented demonstration program.
LaMontagne DS; Nghi NQ; Nga le T; Janmohamed A; Huyen DT; Hien NT; Tsu VD
BMC Public Health; 2014 Jun; 14():556. PubMed ID: 24898950
[TBL] [Abstract][Full Text] [Related]
35. US states shun HPV vaccination.
Tanday S
Lancet Oncol; 2015 Aug; 16(8):e384. PubMed ID: 26190747
[No Abstract] [Full Text] [Related]
36. Human papillomavirus vaccination coverage in Luxembourg - Implications of lowering and restricting target age groups.
Latsuzbaia A; Arbyn M; Weyers S; Mossong J
Vaccine; 2018 Apr; 36(18):2411-2416. PubMed ID: 29602702
[TBL] [Abstract][Full Text] [Related]
37. Inter-state variation in human papilloma virus vaccine coverage among adolescent girls in the 50 US states, 2007.
Kramer MR; Dunlop AL
Matern Child Health J; 2012 Apr; 16 Suppl 1():S102-10. PubMed ID: 22453332
[TBL] [Abstract][Full Text] [Related]
38. Ancillary Benefit of Increased HPV Immunization Rates Following a CBPR Approach to Address Immunization Disparities in Younger Siblings.
Lennon T; Gundacker C; Nugent M; Simpson P; Magallanes NK; West C; Willis E
J Community Health; 2019 Jun; 44(3):544-551. PubMed ID: 30604221
[TBL] [Abstract][Full Text] [Related]
39. HPV vaccine recommendations.
Committee on Infectious Diseases
Pediatrics; 2012 Mar; 129(3):602-5. PubMed ID: 22371460
[TBL] [Abstract][Full Text] [Related]
40. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
Poljak M
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
